Recent Headlines
Within Biotechnology
Baxa Corporation Features Pharmacy Training Programs, Abacus™ Software and ValiMed™ Medication Validation System at the ASHP Summer Meeting
Baxa Corporation is promoting its industry-leading STAR Center pharmacy training facility, CriticalPoint™ online sterile compounding certification training, Abacus TPN ordering and calculation software and the ValiMed System for medication validation at the American Society of Health-System Pharmacists 2007 Summer Meeting and Exhibition beginning today at the Moscone Center in San Francisco. - June 25, 2007 - Baxa Corporation
PharmaChem Publishes AnaSpec Article on Peptides as Antigens
The June issue of PharmaChem, an Italian journal covering the drug discovery industry, featured an article written by AnaSpec called “Peptides as Antigens.” The technical article, written by Dr. Daniel Li and Cecilia Po, outlines the advantages and methodologies behind using peptides as... - June 24, 2007 - AnaSpec, EGT Group
AnaSpec Introduces New SensoLyte™ Beta-Secretase Assay Kit
Leveraging one of the world’s largest collections of amyloid peptides, AnaSpec has introduced its latest development in novel solutions for amyloid-related research - the new SensoLyte™ 520 Beta-Secretase Assay Kit. Beta-secretase catalyzes a key step in the production of beta-amyloid... - June 22, 2007 - AnaSpec, EGT Group
Gamma Medica-Ideas Announces First Sale of a Dual-Head LumaGEM® Molecular Breast Imaging System
Gamma Medica-Ideas Inc. (GM-I), a leader in providing next-generation medical imaging devices for the pre-clinical and clinical markets, announced today the sale of a dual-headed LumaGEM® system for applications such as Molecular Breast Imaging (MBI). This dual head system is the first of its... - June 22, 2007 - Gamma Medica-Ideas
Baxa Corporation and Health Robotics Announce Strategic Alliance to Automate IV Admixture Preparation
Baxa Corporation and Health Robotics announce a strategic alliance to use the Baxa Two-Fer™ Needles with Health Robotics’ CytoCare™ Robot in order to safely and accurately automate the preparation of patient-specific chemotherapy IV admixtures. This alliance combines state-of-the-art technologies to achieve the accuracy and sterility that providers require. The resulting technology is the only totally automated system for handling hazardous IV admixtures available in the market. - June 18, 2007 - Baxa Corporation
University of Kuopio’s A.I. Virtanen Institute Uses Gamma Medica-Ideas’ FLEX Multi-Modality System to Image Baculovirus Biodistribution in Pre-Clinical Subjects
A team of researchers at University of Kuopio’s A.I Virtanen Institute for Molecular Sciences in Finland is conducting studies in non-invasive imaging with Gamma Medica-Ideas’ MicroSPECT/CT system to provide essential information on biodistribution of gene therapy vectors in rats. The... - June 17, 2007 - Gamma Medica-Ideas
Gamma Medica-Ideas Introduces High Resolution CT Subsystem
Gamma Medica-Ideas (GM-I) announced today the addition of a new High Resolution CT subsystem to the company’s FLEX Triumph™ Pre-clinical Imaging Platform that produces striking improvements in CT imaging. The new CT subsystem contains a variable focal spot x-ray source which provides... - June 17, 2007 - Gamma Medica-Ideas
Thrombotargets Corp. and Magellan Bioscience Group, Inc. to Collaborate on Identification of Novel Hits from Both Marine Derivate and Natural Products
Thrombotargets Corporation and Magellan Bioscience Group, Inc. today announced the formation of drug discovery joint venture. Under the terms of this agreement, Magellan Bioscience Group, Inc. will provide to Thrombotargets its compounds and extracts from fermentation broths of marine-isolated... - June 16, 2007 - CoreRx, Inc.
AnaSpec Introduces Industry’s First and Only Anti-MOG ELISA Kits
Drawing on its broad portfolio of MOG (35-55) and other multiple sclerosis (MS) experimental autoimmune encephalomyelitis (EAE)-related peptides, AnaSpec has just released its new line of SensoLyte™ Anti - MOG ELISA Kits - the industry’s first and only anti-MOG ELISA kits. Myelin... - June 16, 2007 - AnaSpec, EGT Group
ValiMed™ Medication Validation System And Related Information From Baxa Corporation Are Now Available At PublicRelationsNewsroom.com
The ValiMed Medication Validation System and related information are now available at PublicRelationsNewsroom.com. The ValiMed System, distributed by Baxa Corporation, offers clinicians a simple and cost-effective tool to ensure medication safety by verifying that medications are correctly compounded. Its patented technology validates compounded doses of high risk medications prior to dispensing. - June 15, 2007 - Baxa Corporation
Baxa Corporation Recognized by Medical Device & Design Industry Magazine for World-Class Quality Team
Baxa Corporation is profiled as one of eight world-class quality and regulatory teams in the June 2007 issue of Medical Device & Diagnostic Industry magazine. The June article was the first time MD&DI recognized the accomplishments of the quality and regulatory teams that ensure medical products are safe and ready for market. - June 13, 2007 - Baxa Corporation
AnaSpec Prepares Technical Poster about Beta-Secretase Assay for Experimental Biology 2007
At the 2007 Experimental Biology conference in Washington, DC, AnaSpec prepared a technical poster entitled, "A Sensitive Fluorimetric Assay for Detection of beta-Secretase Activity Using a Novel FRET Peptide Substrate." The poster documented the following findings: • A highly... - June 08, 2007 - AnaSpec, EGT Group
Clinical Trials in Russia. 1st Quarter 2007 Results
According to Synergy Research Group, a Russia-based CRO, the growth in the number of clinical trials approved by the Russian Federal Agency for Health Care and Social Development (Roszdravnadzor) made up to nearly 40% in the 1st Quarter of 2007 as compared to the same quarter of the previous year. At the same time, the share of clinical studies initiated by Russian manufacturers has increased. - June 06, 2007 - Synergy Research Group
Functional Genetics, Inc. Receives Award to Discover New Opportunities to Combat HIV Infection
Functional Genetics, Inc. Announces a New Award from the National Institute of Allergy and Infectious Diseases to Utilize Its Core Random Homozygous Gene Perturbation and Host-Oriented Therapeutics Technologies to Identify and Validate New Therapeutic Approaches to Combat HIV Infection - June 03, 2007 - Functional Genetics, Inc.
The Imminent Change of the Antithrombotics Market
The antithrombotics market with the two blockbusters enoxaparin and prasugrel is challenged by generic products as well as by next generation anticoagulants with oral administration and antithrombotics with an improved risk-benefit ratio - June 01, 2007 - La Merie Business Intelligence
Novel Agent for Reactive Metabolite Detection
Bioactivation of drug candidates resulting in chemically reactive, electrophilic metabolites have always presented a major challenge to pharmaceutical companies. Moreover, the measurement of these metabolites has been hampered by the lack of an effective quantitative method. QA-GSH is a novel new... - May 31, 2007 - AnaSpec, EGT Group
Colorado BioScience Association Applauds Governor Ritter’s Signing of HB 1060 As Critical To Future Growth of The State’s Bioscience Industry
Colorado Governor Bill Ritter signed House Bill 1060 into law Wednesday afternoon, with the bill sponsors present to acknowledge the importance of the legislation to the bioscience industry in Colorado. Rep. Jim Riesberg (D-Weld) and Sen. Brandon Shaffer (D-Longmont) were thanked for their efforts... - May 25, 2007 - Colorado BioScience Association
Xcelience Will Acquire New Technologies to Enhance Drug Development Processes
The Tampa-based Contract Research Organization signed a partnership that will form new opportunities in the pharmaceutical industry. - May 24, 2007 - Xcelience, LLC
AnaSpec Introduces Line of Insulin Receptor Antibodies
The insulin receptor is a transmembrane receptor that belongs to the tyrosine kinase receptors class. It is a heterotetrameric glycoprotein composed of disulfide-linked subunits in a β-α-α-β configuration. This transmembrane receptor consists of 95kDa β-subunit, a single... - May 23, 2007 - AnaSpec, EGT Group
Baxa Ltd, Subsidiary of Denver-based Baxa Corporation, Announces Direct Sales and Marketing Operations in Switzerland
Baxa Ltd, subsidiary of Denver-based Baxa Corporation, has moved to a direct sales and marketing model for the Swiss market. The company provides systems and devices for simplifying the handling, mixing and administration of fluid medications. Direct operations will provide Baxa Ltd with improved customer access for product development and continuous improvement, while continuing their excellent customer service. - May 21, 2007 - Baxa Corporation
Colorado BioScience Association Names Jack Wheeler Chairperson, Announces 2007 Sponsors and Appoints Eight New Board Members
Jack Wheeler, CEO of MicroPhage, Inc., Longmont, is the new chairperson of the board of directors for the Colorado BioScience Association (CBSA). He was appointed at the association’s 2007 annual meeting April 24th. Wheeler assumes chairperson responsibilities from Ed Wood, ArcScan, Inc. In other action, eight new board members were appointed to three-year terms. - May 18, 2007 - Colorado BioScience Association
Industry’s First West Nile Virus Protease Assay Kits
While West Nile virus (WNV) has had significant outbreaks throughout the world since it was first identified, commercially available assay kits for the detection of WNV protease inhibitors had not been developed until now. With the SensoLyte™ series of WNV Protease Assay Kits AnaSpec, a... - May 17, 2007 - AnaSpec, EGT Group
Baxa Corporation Wins BMA Colorado 2007 Gold Key Award
Baxa Corporation's direct marketing campaign for the Rapid-Fill™ Automated Syringe Filler was awarded a Business Marketing Association Gold Key in the Colorado Chapter’s 2007 competition. Three messages: Safety is Automatic, Technology that Fits and Designed for Speed emphasized the key attributes that differentiate the Baxa product from competitive products and processes. - May 16, 2007 - Baxa Corporation
Clinical Trials in Russia - First Issue of SynRG Orange Paper
On April 25, 2007, the first issue of the Orange Paper – the first analytical review on market of clinical trials in Russia – was officially presented. The strategic goals of Synergy Research Group, a Russia-based emerging CRO, are formation of a civilized market of clinical trials in... - May 16, 2007 - Synergy Research Group
Futuristic Sleep Machine Now Reality
Those seeking improved sleep can switch on Sleep on Command™ device designed to enforce Delta rhythm sleep and the recovery that best occurs during deep, slow-wave, Delta-stage sleep. - May 08, 2007 - EarthPulse Tech, LLC
Baxa Corporation Signs Co-Marketing Agreement with CriticalPoint for Interactive Web-Based Training
Baxa Corporation announces its agreement with CriticalPoint LLC to co-market a Web-based sterile compounding curriculum authored by internationally recognized subject matter experts. This comprehensive, ACPE-approved program consists of 32 modules that meet USP Chapter 797’s competency assessment requirements. Modules are self-paced and part of CriticalPoint’s Learning Management System (LMS), offering access from any Web connection and providing administrative reporting for tracking. - May 07, 2007 - Baxa Corporation
2007-08 Bioscience Colorado Magazine Debuts at BIO International Convention in Boston
Colorado Bioscience Association is releasing the new edition of Bioscience Colorado Magazine at the 2007 BIO International Convention, May 6-9, at the Boston Convention & Exhibition Center. This year’s magazine has expanded to 80 pages and includes an updated directory of the Colorado Bioscience industry: Medical Device and Related Companies; Biotechnology, Pharmaceutical and Related Companies; Biofuels and Related Companies; Research & Education Institutions; Foundations; & Service Providers. - May 06, 2007 - Colorado BioScience Association
“Premature Infants Safer Because Of New Feeding System,” Case Study Now Accessible at PublicRelationsNewsroom.com
“Premature Infants Safer Because Of New Feeding System,” a case study from Premier, Inc., and its member hospitals, in collaboration with Baxa Corporation and VIASYS MedSystems, is now accessible at PublicRelationsNewsroom.com. According to the case, thanks to the collaboration, tiny infants receiving nutrition through feeding tubes now face far less danger from the risk of IV lines and feeding tubes being accidentally connected. - May 03, 2007 - Baxa Corporation
Training Makes a Difference: New Study Finds Farmer Production Costs Decreased, Farmer and Food Safety Increased
Farmers were able to reduce their costs of production, while more effectively controlling pests and better protecting themselves and their farms – all thanks to a practical training programme with farmers in rural China. “Responsible use of crop protection products increases food... - May 01, 2007 - CropLife Asia
Baxa Corporation Announces Enteral Syringes Now on Contract with AmeriNet, MedAssets, Novation and Premier Group Purchasing Organizations
Baxa Corporation announces its new syringes, designed for enteral feeding only, have been accepted on contract with key group purchasing organizations to facilitate hospital compliance with patient safety goals and to prevent wrong-route errors. Contracts for enteral syringes have been made between Baxa and these top US group purchasing organizations: AmeriNet, MedAssets, Novation and Premier. - April 30, 2007 - Baxa Corporation
Artificial Sun for Cell Culture Heating
The LAMBDA MINIFOR fermenter / bioreactor provides a new heating system for precise, fast and economic heating of the culture medium in fermentation and cell culture processes - April 29, 2007 - LAMBDA Laboratory Instruments
Baxa Corporation Features Pharmacy Automation and Dedicated Oral Dispensers at the Interphex 2007 Exhibition
Baxa Corporation is promoting its industry-leading products for automating pharmacy filling operations and safe dispensing of oral liquid medications at the annual Interphex Conference and Exhibition beginning today at the Jacob K. Javits Convention Center in New York City. The annual Interphex Conference brings together global companies serving the pharmaceutical and biotechnical industries. - April 24, 2007 - Baxa Corporation
Interleukin & Chemokine Antibodies – Two Types of Cytokine Antibodies
Interleukin-32 (IL-32), whose expression is increased following activation by IL-2, was initially identified as a transcript (NK4) selectively expressed in lymphocytes and NK cells.1 - April 18, 2007 - AnaSpec, EGT Group
Baxa Praises the UK’s NPSA Patient Safety Alert Advising Hospitals to Switch to Safer Oral/Enteral Syringes
The UK’s National Patient Safety Agency (NPSA) has released a Patient Safety Alert detailing the hazards of wrong-route administration and recommending immediate actions to ensure that oral/enteral medications cannot be administered through an intravenous connection. Hospitals can comply with the Patient Safety Alert immediately using the Exacta-Med® Oral/Enteral Dispensers from Baxa Ltd, Baxa Corporation’s UK subsidiary. - April 17, 2007 - Baxa Corporation
ABRF Poster Presents Comparison of Fluorescent Peptide Synthesis Methods
At the 2007 annual conference of the Association of Biomolecular Resource Facilities, AnaSpec presented a technical poster that compared the synthesis of a fluorescent peptide using two types of resins. The results of the poster indicated that the use of an unprotected resin was just as effective... - April 13, 2007 - AnaSpec, EGT Group
New Dye Solution for Far Red to NIR Imaging
Utilizing its proprietary HiLyte Fluor™ technology, AnaSpec has introduced dye solutions for far red to NIR imaging. AnaSpec’s HiLyte Fluor™ 647, HiLyte Fluor™ 680, and HiLyte Fluor™ 750 provide AnaSpec with a range of dyes that cover the spectrum. AnaSpec has also... - April 11, 2007 - AnaSpec, EGT Group
AnaSpec Introduces AnaTag™ Protein Labeling Kits
The labeling of proteins and antibodies with fluorescent dyes can play a crucial role in flow cytometry, immunohistochemistry and fluorescent in-situ hybridization techniques. Incorporating its high performance HiLyte Fluor™ dyes in a ready-to-use kit, AnaSpec has introduce its new line of... - April 04, 2007 - AnaSpec, EGT Group
Colorado Bioscience Association Launches Colorado Springs Chapter
The debut of the Colorado Springs Chapter of the Colorado Bioscience Association (CBSA) occurred yesterday at the University of Colorado at Colorado Springs (UCCS). The announcement is made by Denise Brown, CBSA Executive Director, who says UCCS Chancellor Pam Shockley hosted the chapter launch event. - March 29, 2007 - Colorado BioScience Association
AnaSpec Launches Optimized Website
In an effort to optimize the online experience of its customers, AnaSpec, a worldwide provider of integrated proteomics solutions, has moved its website to a faster, dedicated server. AnaSpec sales & marketing manager, Violeta Rajkovska, MBA, stated, “With the huge number of catalog... - March 28, 2007 - AnaSpec, EGT Group
Baxa Corporation Launches Educational Campaign Highlighting the Risks of Enteral Tubing Misconnections
Campaign for Baxa dedicated enteral systems focuses on educating providers on the risks, especially for neonatal patients, of wrong-route administration of non-IV fluids. While tubing misconnections can be deadly for any patient, neonates represent the highest risk population due to their small size and other health complications. The campaign launch closely follows the January 2007 release by the Joint Commission of their proposed 2008 National Patient Safety Goals (NPSGs) for comment. - March 21, 2007 - Baxa Corporation
Bio3 Research S.r.l., Milan – Italy, Has Been Granted by the Australian Patent Office a Patent in the Field of HMGB1
Bio3 Research S.r.l., Milan – Italy, has been granted by the Australian Patent Office a patent in the field of cardiovascular diseases related to HMGB1 over-expression and for the use of HMGB1 protein in connective tissue regeneration. - March 16, 2007 - Bio3 Research S.r.l.
Two Colorado Bioscience Legislative Initiatives Rank Among BIO’s Best Practices in the Nation
Two Colorado bioscience legislative initiatives are included in the national BIO “State Legislative Best Practices in Support of Bioscience Industry Development,” report issued late last year for state legislation promoting growth of bioscience clusters in 2005-06. Of the 23 standout initiatives, only two other states, California and Texas, had two projects highlighted. - March 14, 2007 - Colorado BioScience Association
Name Change: AnaSpec’s EnzoLyte is now SensoLyte™
AnaSpec, a worldwide provider of integrated proteomics solutions, announced today that the name of their flagship line of high-performance assay kits has been changed from EnzoLyte to SensoLyte™. AnaSpec sales & marketing manager, Violeta Rajkovska, MBA, noted, “The new name... - March 14, 2007 - AnaSpec, EGT Group
Xcelience Employs "CFS1200 Capsule Filling and Sealing Machine"
Xcelience's implementation of the CFS1200 will allow its formulation scientists the opportunity to accelerate the drug development timeframe. - March 13, 2007 - Xcelience, LLC
Xcelience Completes Successful QP Audit of Production Facility for European Market
Xcelience achives its third successful audit. - March 09, 2007 - Xcelience, LLC
The New Class of Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Has One Clear Leader and Many Followers
Merck & Co clearly leads the field of DPP-IV inhibitors which has many followers in clinical development. The first companies already abandoned the field. - March 05, 2007 - La Merie Business Intelligence
Four Colorado Companies Participate at the 2007 Rocky Mountain Bioscience Venture Capital Meeting on the Mountain in Park City, Utah
Four Colorado-based companies are participating at the 2007 Rocky Mountain Bioscience Venture Capital Meeting on the Mountain, March 2-4, at the Park City (UT) Marriott. Dorsey & Whitney, lead sponsor of the event, hosts venture capitalists and area companies to learn and explore bioscience opportunities in the Rocky Mountain Region. Co-sponsors include UV Partners, vSpring Capital and Wasatch Venture Fund. - March 04, 2007 - Colorado BioScience Association
Xcelience Debuts its Innovative and Interactive Forum: XpertXchange™
XpertXchange will initiate dialogue between Xcelience scientists and drug development professionals. - March 02, 2007 - Xcelience, LLC
TOP Classes of Biologics with 2006 Sales of US$ 63.8 bln
Sales of the major cancer antibodies grew by 57 % to US$ 10.6 bln in 2006. Cancer antibodies are challenging the still No. 1 selling class of erythropoietins with 2006 sales of US$ 11.9 bln, but the lowest growth rate (6.4%), and got ahead of TNF antibodies which posted sales of 10.3 bln (+ 25%). - February 27, 2007 - La Merie Business Intelligence
Automated Internal Perfusion for the Port-a-Patch
Nanion Technologies introduces the Internal Perfusion System for the Port-a-Patch; a completely unique device for rapid, continuous and automated exchange of internal solutions during patch clamp recordings. Using the internal perfusion system, ion channels regulated by internal binding sites... - February 27, 2007 - Nanion Technologies GmbH